Pink SheetNovartis could soon learn whether the European Medicines Agency will agree to fast track its review of the company’s planned EU marketing application for an intrathecal formulation of the spinal muscu
Pink SheetCommercializing cell and gene therapies is notoriously challenging, and while pricing is often seen as a key problem, companies must also consider how their product fits in logistically with health ca
ScripPfizer’s recent exit from gene therapies was not an indictment of the safety and efficacy of gene and cellular therapies. Rather it was the latest example of the difficulties in commercializing these
ScripSanofi’s multiple sclerosis candidate tolebrutinib is in line for a potential US approval in the autumn after the Food and Drug Administration agreed to a speedy review of the oral Bruton’s tyrosine k